Understand the source comparison
Peptides for Bloating and Gas — Comparison
BPC-157 Nitric oxide modulation, VEGF signaling, mucosal healing Gastric motility normalisation, reduces delayed emptying and gas accumulation Preclinical only. 40+ animal studies, limited human case reports 200–500mcg daily subcutaneous or 500–1000mcg oral St
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Nitric oxide modulation, VEGF signaling, mucosal healing
- Gastric motility normalisation, reduces delayed emptying and gas accumulation
- Preclinical only. 40+ animal studies, limited human case reports
- 200–500mcg daily subcutaneous or 500–1000mcg oral
- Strongest mechanistic rationale for motility-related bloating. No RCTs but consistent gastroprotective data
- KPV
- NF-kB inhibition, TNF-alpha suppression
- Reduces mucosal inflammation and gut wall edema that amplifies bloating perception
- Phase I safety data + small open-label IBD trial
- 5–10mg oral daily
- Best for inflammation-driven bloating. Won't address SIBO or motility issues
- Thymosin Beta-4
- Tight junction protein upregulation, epithelial migration
- Restores barrier function, reduces endotoxin translocation and visceral edema
- Preclinical barrier function studies. No direct GI symptom trials
- 2.5–5mg subcutaneous twice weekly
- Weakest direct evidence for bloating. Mechanism is plausible but entirely theoretical
- MK-677 (Ibutamoren)
- Growth hormone secretagogue. Increases ghrelin and GH release
- May worsen bloating by increasing appetite and delaying gastric emptying
- Not indicated for GI symptoms. Used for muscle growth research
- 10–25mg oral daily
- Contraindicated. Ghrelin elevation can exacerbate bloating and water retention